Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971228 · ClinicalTrials.gov registry record · Phase 2
Feasibility Trial Testing the Bionic Pancreas With ZP4207
A Phase 2 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02971228 is a Phase 2 study that has completed, run by Zealand Pharma. The registered enrollment target is 13 participants.
The verdict
NCT02971228, a Phase 2 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon\*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Interventions
- DRUG Glucagon
- DRUG Insulin Lispro
- DRUG ZP4207 (dasiglucagon)
- DEVICE iPhone-based bionic pancreas
- DEVICE iLet-based bionic pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02971228
The ClinicalTrials.gov registry entry for NCT02971228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Glucagon is the first listed.
NCT02971228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02971228 about?
NCT02971228 is a clinical study titled "Feasibility Trial Testing the Bionic Pancreas With ZP4207". The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon\*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
What is the current status of trial NCT02971228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2016-11. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT02971228?
The interventions under investigation include: Glucagon (DRUG), Insulin Lispro (DRUG), ZP4207 (dasiglucagon) (DRUG), iPhone-based bionic pancreas (DEVICE), iLet-based bionic pancreas (DEVICE).
Who is sponsoring clinical trial NCT02971228?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.